Novartis unit AveXis has entered a manufacturing agreement with researchers at Massachusetts Eye and Ear and Massachusetts General Hospital in the US to produce a genetic vaccine against Covid-19, AAVCOVID.
AveXis will leverage its gene therapy manufacturing expertise to produce and scale the AAVCOVID vaccine candidate, which uses adeno-associated virus (AAV) vector, for clinical trials.
The company will start producing the vaccine this month. Currently, the vaccine is being tested for safety and efficacy in preclinical studies at various academic medical institutions, including Massachusetts Eye and Ear.
For manufacturing the vaccine, AveXis will use its AAV technology designed for the treatment of rare, life-threatening neurological